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CUTANEOUS RADIATION INJURY
Injury to the skin and underlying tissues from acute exposure to 
a large external dose of radiation is referred to as cutaneous 
radiation injury (CRI). Acute radiation syndrome (ARS) 1 will 
usually be accompanied by some skin damage; however, CRI 
can occur without symptoms of ARS. This is especially true with 
acute exposures to beta radiation or low-energy x-rays, because 
beta radiation and low-energy x-rays are less penetrating and less 
likely to damage internal organs than gamma radiation is. CRI can 
occur with radiation doses as low as 2 Gray (Gy) or 200 rads 2 and 
the severity of CRI symptoms will increase with increasing doses. 
Most cases of CRI have occurred when people inadvertently came 
in contact with unsecured radiation sources from food irradiators, 
radiotherapy equipment, or well depth gauges. In addition, cases of 
CRI have occurred in people who were overexposed to x-radiation 
from fluoroscopy units.
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Early signs and symptoms of CRI are itching, tingling, or a transient 
erythema or edema without a history of exposure to heat or caustic 
chemicals. Exposure to radiation can damage the basal cell layer 
of the skin and result in inflammation, erythema, and dry or moist 
desquamation. In addition, radiation damage to hair follicles can 
cause epilation. Transient and inconsistent erythema (associated 
with itching) can occur within a few hours of exposure and be 
followed by a latent, symptom-free phase lasting from a few days to 
several weeks. After the latent phase, intense reddening, blistering, 
and ulceration of the irradiated site are visible. Depending on 
the radiation dose, a third and even fourth wave of erythema are 
possible over the ensuing months or possibly years.
In most cases, healing occurs by regenerative means; however, 
large radiation doses to the skin can cause permanent hair loss, 
damaged sebaceous and sweat glands, atrophy, fibrosis, decreased 
or increased skin pigmentation, and ulceration or necrosis of the 
exposed tissue.
With CRI, it is important to keep the following things in mind:
• The visible skin effects depend on the magnitude of the dose as 
well as the depth of penetration of the radiation.
• Unlike the skin lesions caused by chemical or thermal damage, 
the lesions caused by radiation exposures do not appear for hours 
to days following exposure, and burns and other skin effects tend 
to appear in cycles.
• The key treatment issues with CRI are infection and pain 
management.3
STAGES AND 
GRADES OF CRI
CRI will progress over time in stages and can be categorized by 
grade, with characteristics of the stages varying by grade of injury, 
as shown in Table 1. Appendix A gives a detailed description of the 
various skin responses to radiation, and Appendix B provides color 
photographs of examples of some of these responses.
1 The Gray (Gy) is a unit of absorbed dose and refl ects an amount of energy 
deposited into a mass of tissue (1 Gy = 100 rads). In this document, the 
referenced absorbed dose is that dose inside the patient’s body (i.e., the 
dose that is normally measured with personal dosimeters).
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Prodromal stage (within hours of exposure)—This stage is 
characterized by early erythema (first wave of erythema), heat 
sensations, and itching *
that define the exposure area. The duration of this stage is from 1 
to 2 days.
Latent stage (1–2 days postexposure)—No injury is evident. 
Depending on the body part, the larger the dose, the shorter this 
period will last. The skin of the face, chest, and neck will have a 
shorter latent stage than will the skin of the palms of the hands or 
the soles of the feet.
Manifest illness stage (days to weeks postexposure)—The basal 
layer is repopulated through proliferation of surviving clonogenic 
cells. This stage begins with main erythema (second wave), a 
sense of heat, and slight edema, which are often accompanied by 
increased pigmentation. The symptoms that follow vary from dry 
desquamation or ulceration to necrosis, depending on the severity 
of the CRI (see Table 1).
Third wave of erythema (10–16 weeks postexposure, especially after 
beta exposure)—The exposed person experiences late erythema, 
injury to blood vessels, edema, and increasing pain. A distinct bluish 
color of the skin can be observed. Epilation may subside, but new 
ulcers, dermal necrosis, and dermal atrophy (and thinning of the 
dermis layer) are possible.
Late effects (months to years postexposure; threshold dose ~10 
Gy or 1000 rads)—Symptoms can vary from slight dermal atrophy 
(or thinning of dermis layer) to constant ulcer recurrence, dermal 
necrosis, and deformity. Possible effects include occlusion of small 
blood vessels with subsequent disturbances in the blood supply 
(telangiectasia); destruction of the lymphatic network; regional 
lymphostasis; and increasing invasive fibrosis, keratosis, vasculitis, 
and subcutaneous sclerosis of the connective tissue. Pigmentary 
changes and pain are often present. Skin cancer is possible in 
subsequent years.
Recovery (months to years)
2 The referenced absorbed dose levels in this document are assumed to 
be from beta, gamma, or x radiation. Neutron or proton radiation produces 
many of the health effects described herein at lower absorbed dose levels. 
3 The dose may not be uniform, but a large portion of the body must have 
received more than 0.7 Gy (70 rads).
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PATIENT  
MANAGEMENT
DIAGNOSIS
The signs and symptoms of CRI are as follows:
• Intensely painful burn-like skin injuries (including itching, tingling, 
erythema, or edema) without a history of exposure to heat or 
caustic chemicals Note: Erythema will not be seen for hours to 
days following exposure, and its appearance is cyclic.
• Epilation
• A tendency to bleed
• Possible signs and symptoms of ARS
As mentioned previously, local injuries to the skin from acute 
radiation exposure evolve slowly over time, and symptoms may 
not manifest for days to weeks after exposure. Consider CRI in the 
differential diagnosis if the patient presents with a skin lesion without 
a history of chemical or thermal burn, insect bite, or skin disease or 
allergy. If the patient gives a history of possible radiation exposure 
(such as from a radiography source, x-ray device, or accelerator) or 
a history of finding and handling an unknown metallic object, note 
the presence of any of the following: erythema, blistering, dry or 
wet desquamation, epilation, ulceration.
Regarding lesions associated with CRI be aware that,
• days to weeks may pass before lesions appear;
• unless patients are symptomatic, they will not require emergency 
care; and
• lesions can be debilitating and life threatening after several weeks.
Medical follow-up is essential, and victims should be cautioned to 
avoid trauma to the involved areas.
INITIAL TREATMENT
Localized injuries should be treated symptomatically as they 
occur, and radiation injury experts should be consulted for detailed 
information. Such information can be obtained from the Radiation 
Emergency Assistance Center/Training Site (REAC/TS) at www.
orau.gov/reacts/ or (865) 576-1005.
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As with ARS, if the patient also has other trauma, wounds should 
be closed, burns covered, fractures reduced, surgical stabilization 
performed, and definitive treatment given within the first 48 hours 
after injury. After 48 hours, surgical interventions should be delayed 
until hematopoietic recovery has occurred.
A baseline CBC and differential should be taken and repeated in 24 
hours. Because cutaneous radiation injury is cyclic, areas of early 
erythema should be noted and recorded. These areas should also be 
sketched and photographed, if possible, ensuring that the date and 
time are recorded. The following should be initiated as indicated:
• Supportive care in a clean environment (a burn unit if one is 
available)
• Prevention and treatment of infections
• Use of the following:
 ° Medications to reduce inflammation, inhibit protealysis, relieve 
pain, stimulate regeneration, and improve circulation
 ° Anticoagulant agents for widespread and deep injury
• Pain management
• Psychological support
RECOMMENDATIONS FOR TREATMENT BY STAGE
The following recommendations for treatment by stage of the 
illness were obtained by summarizing recommendations from Ricks 
et al. (226) and Gusev et al. (231), but they do not represent official 
recommendations of CDC.
Prodromal Stage —Use antihistamines and topical antipruriginous 
preparations, which act against itch and also might prevent or 
attenuate initiation of the cycle that leads to the manifestation 
stage. Anti-inflammatory medications such as corticosteroids and 
topical creams, as well as slight sedatives, may prove useful.
Latent Stage —Continue anti-inflammatory medications and 
sedatives. At midstage, use proteolysis inhibitors, such as Gordox®.
Manifestation Stage —Use repeated swabs, antibiotic prophylaxis, 
and anti-inflammatory medications, such as Lioxasol®, to reduce 
bacterial, fungal, and viral infections.
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• Apply topical ointments containing corticosteroids along with 
locally acting antibiotics and vitamins.
• Stimulate regeneration of DNA by using Lioxasol® and later, when 
regeneration has started, biogenic drugs, such as Actovegin® and 
Solcoseril®.
• Stimulate blood supply in third or fourth week using Pentoxifylline® 
(contraindicated for patients with atherosclerotic heart disease).
• Puncture blisters if they are sterile, but do not remove them as 
long as they are intact.
• Stay alert for wound infection. Antibiotic therapy should be 
considered according to the individual patient’s condition.
• Treat pain according to the individual patient’s condition. Pain 
relief is very difficult and is the most demanding part of the 
therapeutic process.
• Debride areas of necrosis thoroughly but cautiously.
TREATMENT OF LATE EFFECTS
After immediate treatment of radiation injury, an often long and 
painful process of healing will ensue. The most important concerns 
are the following:
• Pain management
• Fibrosis or late ulcers
• Note: Use of medication to stimulate vascularization, inhibit 
infection, and reduce fibrosis may be effective. Examples include 
Pentoxifylline®, vitamin E, and interferon gamma. Otherwise, 
surgery may be required.
• Necrosis
• Plastic/reconstructive surgery
• Note: Surgical treatment is common. It is most effective if 
performed early in the treatment process. Full-thickness graft and 
microsurgery techniques usually provide the best results.
• Psychological effects, such as posttraumatic stress disorder
• Possibility of increased risk of skin cancer later in life
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FOR MORE  
ASSISTANCE
Technical assistance can be obtained from the Radiation Emergency 
Assistance Center/Training Site (REAC/TS) at (865) 576-3131 (M-
F, 8 AM to 4:30 PM EST) or (865) 576-1005 (after hours), or at 
http://www.orau.gov/reacts/, and from the Medical Radiobiology 
Advisory Team (MRAT) at (301) 295-0316.
Also, more information can be obtained from the CDC Health Alert 
Network at emergency.cdc.gov or 1-800-311-3435.
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APPENDIX A: Responses of the Skin to Radiation
Acute epidermal necrosis (time of onset: < 10 days postexposure; 
threshold dose: ~550 Gy or 55,000 rads)
Interphase death of postmitotic keratinocytes in the upper visible 
layers of the epidermis (may occur with high-dose, low-energy 
beta irradiation)
Acute ulceration (time of onset: < 14 days postexposure; threshold 
dose: ~20 Gy or 2000 rads)
Early loss of the epidermis— and to a varying degree, deeper 
dermal tissue—that results from the death of fibroblasts and 
endothelial cells in interphase
Dermal atrophy (time of onset: > 26 weeks postexposure; threshold 
dose: ~10 Gy or 1000 rads)
Thinning of the dermal tissues associated with the contraction of 
the previously irradiated area
Dermal necrosis (time of onset > 10 weeks postexposure; threshold 
dose: ~20 Gy or 2000 rads)
Necrosis of the dermal tissues as a consequence of vascular 
insufficiency
Dry desquamation (time of onset: 3–6 weeks postexposure; threshold 
dose: ~8 Gy or 800 rads)
Atypical keratinization of the skin caused by the reduction in the 
number of clonogenic cells within the basal layer of the epidermis
Early transient erythema (time of onset: within hours of exposure; 
threshold dose: ~2 Gray [Gy] or 200 rads)
Inflammation of the skin caused by activation of a proteolytic 
enzyme that increases the permeability of the capillaries
Epilation (time of onset: 14–21 days; threshold dose: ~3 Gy or 300 rads)
Hair loss caused by the depletion of matrix cells in the hair follicles 
Late erythema (time of onset: 8–20 weeks postexposure; threshold 
dose: ~20 Gy or 2000 rads)
Inflammation of the skin caused by injury of blood vessels. Edema 
and impaired lymphatic clearance precede a measured reduction 
in blood flow.
Invasive fibrosis (time of onset: months to years postexposure; 
threshold dose: ~20 Gy or 2000 rads)
Method of healing associated with acute ulceration, secondary 
ulceration, and dermal necrosis that leads to scar tissue formation
Main erythema (time of onset: days to weeks postexposure; threshold 
dose: ~3 Gy or 300 rads)
Inflammation of the skin caused by hyperaemia of the basal cells 
and subsequent epidermal hypoplasia (see photos 1 and 2)
8
Moist desquamation (time of onset: 4–6 weeks postexposure; threshold 
dose: ~15 Gy or 1500 rads)
Loss of the epidermis caused by sterilization of a high proportion 
of clonogenic cells within the basal layer of the epidermis
Secondary ulceration (time of onset: > 6 weeks postexposure; threshold 
dose: ~15 Gy or 1500 rads)
Secondary damage to the dermis as a consequence of dehydration 
and infection when moist desquamation is severe and protracted 
because of reproductive sterilization of the vast majority of the 
clonogenic cells in the irradiated area
Telangiectasia (time of onset: > 52 weeks postexposure; threshold 
dose for moderate severity at 5 years: ~40 Gy or 4000 rads)
Atypical dilation of the superficial dermal capillaries
APPENDIX B: IMAGES
Figures 1 & 2 
Erythema
(Photos courtesy 
of Gusev IA and 
reprinted with 
permission)
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These photos display the progression of erythema in a patient involved 
in an x-ray diffraction accident, 9 days to 96 days postexposure. 
The day following the exposure (not shown), the patient displayed 
only mild diffuse swelling and erythema of the fingertips. On day 
9, punctuate lesions resembling telangiectasias were noted in the 
subungal region of the right index finger, and on day 11, blisters 
began to appear. Desquamation continued for several weeks. The 
patient developed cellulitis in the right thumb approximately 2 
years following exposure. The area of the right fingertip and nail 
continued to cause the patient great pain when even minor trauma 
occurred to the fingertip, and he required occasional oral narcotic 
analgesics to manage this pain. He continued to experience intense 
pain resulting from minor trauma to the affected areas for as long 
as 4 years postexposure.
Figures 3  
& 4 Acute  
ulceration
(Photos courtesy 
of Ricks RC and 
reprinted with 
permission)
Acute ulceration. These photos show acute ulceration in a Peruvian 
patient who inadvertently placed a 26-Ci (0.962-TBq) irridiun-192 ( 
192 Ir) source in his back pocket, 3 days and 10 days postexposure. 
The source remained in the patient’s pocket for approximately 6.5 
hours, at which time he complained to his wife about pain in his 
posterior right thigh. He sought medical advice and was told he 
probably had been bitten by an insect. In the meantime, his wife sat 
on the patient’s pants (her case appears on the next page) while 
breastfeeding the couple’s 1½-year-old child.
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The source was recovered several hours later by nuclear regulatory 
authorities, and the patient was transported to Lima for treatment. 
This patient exhibited a drastic reduction in lymphocyte count by 
day 3 postexposure, and a 4-by-4-cm lesion appeared on day 4. 
Eventually he suffered with a massive ulceration and necrosis of the 
site with infection, and his right leg was amputated. Grade II and III 
CRI was also evident on his hands, left leg, and perineum, but he 
survived and returned to his family.
Figures 5  
Moist  
desquamation
(Photos courtesy 
of Ricks RC and 
reprinted with 
permission)
Moist desquamation. This patient is the wife of the previous case 
study, 26 days postexposure. She was exposed to the 192 Ir source 
when she sat on her husband’s pants (still containing the source) for 
approximately 20 minutes after he had changed clothes that evening.
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Figures 6  
Necrosis,  
fibrosis, and 
telangiectasia
(Photos courtesy 
of Ricks RC and 
reprinted with 
permission)
Necrosis, fibrosis, and telangiectasia. Same patient, 2 years 
following exposure.
1. See “Acute Radiation Syndrome: A Fact Sheet for Physicians” at 
emergency.cdc.gov/radiation/arsphysicianfactsheet.asp.
2. Both the Gray (Gy) and the rad are units of absorbed dose and 
reflect the amount of energy deposited in a mass of tissue (1 
Gy = 100 rads). In this document, the absorbed dose refers to 
that dose received by at least 10 cm 2 of the basal cell layer of 
the skin. The referenced absorbed dose levels in this document 
are assumed to be from beta, gamma, or x-radiation. Neutron or 
proton radiation produces many of the health effects described 
herein at lower absorbed dose levels.
3. On occasion a patient might also be contaminated with 
radioactive material. To address patient decontamination, please 
go to the following Web site: http://www.orau.gov/reacts/
emergency.htm
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Table 1: Grades 
of Cutaneous 
Radiation Injury
4 Absorbed dose to at least 10 cm2 of the basal cell layer of the skin.
5 Especially with beta exposure
6 The Gray (Gy) is a unit of absorbed dose and reflects an amount of energy deposited in a mass of tissue (1 Gy = 100 rads). 
7 Skin of the face, chest, and neck will have a shorter latent phase than the skin of the palms of the hands and the soles of the feet.
GRADE SKIN DOSE*
PRODROMAL 
STAGE
LATENT 
STAGE MANIFEST ILLNESS STAGE
THIRD WAVE OF 
ERYTHEMA5 RECOVERY LATE EFFECTS
I
> 2 Gy 
(200 
rads)6
1–2 days 
postexposure 
or not seen
no injury  
evident for 
2–5 weeks 
postexposure7
• 2–5 weeks postexposure, lasting 
20–30 days: redness of skin, 
slight edema, possible increased 
pigmentation
• 6–7 weeks postexposure, dry 
desquamation
not seen
complete healing 
expected 28–40 
days after dry 
desquamation 
(3–6 months 
postexposure)
• possible slight skin atrophy
• possible skin cancer decades after 
exposure
II
> 15 Gy 
(1500 
rads) 
6–24 hours 
postexposure 
with immediate 
sensation of 
heat lasting  
1–2 days
no injury  
evident for 
1-3 weeks 
postexposure
• 1–3 weeks postexposure; redness 
of skin, sense of heat, edema, skin 
may turn brown
• 5–6 weeks postexposure, edema 
of subcutaneous tissues and 
blisters with moist desquamation 
• possible epithelialization later
 10–16 weeks 
postexposure, 
injury of blood 
vessels, edema, 
and increasing 
pain
 epilation may 
subside, but 
new ulcers and 
necrotic changes 
are possible
healing depends 
on size of 
injury and the 
possibility of 
more cycles of 
erythema
• possible skin atrophy or ulcer 
recurrence
• possible telangiectasia (up to 10 
years postexposure)
• possible skin cancer decades after 
exposure
III
> 40 Gy 
(4000 
rads) 
4–24 hours 
postexposure, 
with immediate 
pain or  
tingling lasting 
1–2 days
none or less 
than 2 weeks
• 1–2 weeks postexposure: redness 
of skin, blisters, sense of heat, 
slight edema, possible increased 
pigmentation followed by 
erosions and ulceration as well as 
severe pain
 10–16 weeks 
postexposure: 
injury of blood 
vessels, edema, 
new ulcers, and 
increasing pain
possible necrosis
can involve 
ulcers that 
are extremely 
difficult to treat 
and that can 
require months 
to years to heal 
fully
• possible skin atrophy, 
depigmentation, constant ulcer 
recurrence, or deformity
• possible occlusion of small vessels 
with subsequent disturbances in 
the blood supply, destruction of 
the lymphatic network, regional 
lymphostasis, and increasing 
fibrosis and sclerosis of the 
connective tissue
• possible telangiectasia
• possible skin cancer decades after 
exposure
IV
> 550 
Gy 
(55,000 
rads) 
occurs minutes 
to hours 
postexposure,  
with immediate 
pain or tingling, 
accompanied 
by swelling
none
• 1–4 days postexposure 
accompanied by blisters
• early ischemia (tissue turns white, 
then dark blue or black with 
substantial pain) in most severe 
cases
• tissue becomes necrotic within 
2  weeks following exposure, 
accompanied by substantial pain
does not occur 
due to necrosis 
of skin in the 
effected area
recovery possible 
following 
amputation of 
severely affected 
areas  and 
possible skin 
grafts
• continued plastic surgery may be 
required over several years
• possible skin cancer decades after 
exposure
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